ArticleScience immunology2023
CD4 binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wild-type animals.
Open access · hybridAbstract read
In one paragraph
Article in Science immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 30 citations in OpenAlex.
- Article
- Protocol for an in vivo CRISPR screen for germinal center B cells in mice using ecotropic retrovirus.STAR protocols · 2026Article
- Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design.Science (New York, N.Y.) · 2026Article
- Maturation of HIV-1 neutralizing antibodies in a germinal center conditional expression mouse model.PLoS pathogens · 2026Article
- Divalent HIV-1 gp120 Immunogen Exhibits Selective Avidity for Broadly Neutralizing Antibody VRC01 Precursors.Vaccines · 2026Article
- Accelerating Innovation: Advancing Opportunities in HIV Vaccine Development.Current HIV research · 2026Review
- Integration of Preclinical and Clinical Vaccine Safety and Immunogenicity Testing for Development of a Pediatric HIV Vaccine to Achieve Protective HIV Immunity Prior to Adolescence.Current HIV research · 2026Review
- Germline-Targeting Strategies to Induce bNAbs against HIV-1.Current HIV research · 2026Review
- Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy.Nature immunology · 2025Article
- The HIV-1 envelope glycoprotein: structure, function and interactions with neutralizing antibodies.Nature reviews. Microbiology · 2025Review
- Consistent Induction of Broadly Neutralizing HIV Antibodies by a Novel Two-Step Mechanism Informs Immunogen Design.bioRxiv : the preprint server for biology · 2025Article
- Design and characterization of HIV-1 vaccine candidates to elicit antibodies targeting multiple epitopes.The Journal of experimental medicine · 2025Article
- Scale-up and cGMP manufacturing of next-generation vaccine adjuvant saponin/MPLA nanoParticles (SMNP).Journal of pharmaceutical sciences · 2025Article
- Structural insights into VRC01-class bnAb precursors with diverse light chains elicited in the IAVI G001 human vaccine trial.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Transient glycan shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaques.Cell reports · 2025Article
- Vaccines combining slow release and follicle targeting of antigens increase germinal center B cell diversity and clonal expansion.Science translational medicine · 2025Article
- Article
- Designed mosaic nanoparticles enhance cross-reactive immune responses in mice.bioRxiv : the preprint server for biology · 2024Article
- Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques.Cell · 2024Article
- Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates.Immunity · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 7 institutions in 2 countries.
Harry B GristickDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0000-0002-1957-2821
Harald HartwegerLaboratory of Molecular Immunology, Rockefeller University, New York, NY 10065, USA.ORCID 0000-0002-1118-1818
Maximilian LoeweLaboratory of Molecular Immunology, Rockefeller University, New York, NY 10065, USA.ORCID 0000-0003-2935-3750
Jelle van SchootenDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0000-0002-5202-355X
Victor RamosLaboratory of Molecular Immunology, Rockefeller University, New York, NY 10065, USA.ORCID 0000-0001-7353-3420
Thiago Y OliveiraLaboratory of Molecular Immunology, Rockefeller University, New York, NY 10065, USA.ORCID 0000-0002-2654-0879
Yoshiaki NishimuraLaboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-1347-2368
Nicholas S KorandaDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Abigail WallVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0001-8198-2138
Kai-Hui YaoLaboratory of Molecular Immunology, Rockefeller University, New York, NY 10065, USA.
Daniel PostonLaboratory of Molecular Immunology, Rockefeller University, New York, NY 10065, USA.ORCID 0000-0001-9900-6717
Anna GazumyanLaboratory of Molecular Immunology, Rockefeller University, New York, NY 10065, USA.ORCID 0000-0002-5976-9717
Marie WiatrLaboratory of Molecular Immunology, Rockefeller University, New York, NY 10065, USA.
Marcel HorningLaboratory of Molecular Immunology, Rockefeller University, New York, NY 10065, USA.ORCID 0000-0003-1468-4645
Jennifer R KeeffeDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0000-0002-5317-6398
Magnus A G HoffmannDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0000-0003-4923-9568
Zhi YangDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0000-0001-8680-3784
Morgan E AbernathyDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Kim-Marie A DamDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0000-0002-1416-4757
Han GaoDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Priyanthi N P GnanapragasamDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Leesa M KakutaniDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0000-0003-3822-7449
Ana Jimena Pavlovitch-BedzykDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0000-0001-6444-3562
Mark HowarthDepartment of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK.ORCID 0000-0001-8870-7147
Andrew T McGuireVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0003-1841-6859
Leonidas StamatatosVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0002-1106-7097
Malcolm A MartinLaboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-1232-2966
Anthony P WestDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0000-0003-4213-5184
Michel C NussenzweigLaboratory of Molecular Immunology, Rockefeller University, New York, NY 10065, USA.ORCID 0000-0003-0592-8564
Pamela J BjorkmanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0000-0002-2277-3990
California Institute of Technology · USRockefeller University · USUniversity of Washington · USNational Institutes of Health · USBeth Israel Deaconess Medical Center · USHoward Hughes Medical Institute · USUniversity of Oxford · GB
Funding
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6MStuctural basis of bNab activityP01AI100148 · NIAID · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI Pamela J Bjorkman · 2013 to 2026
$43.3MCHEETAH Center for the Structural Biology of HIV Infection, Restriction, and Viral DynamicsU54AI170856 · NIAID · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI CHRISTOPHER P. HILL · 2022 to 2026
$34.4MThe Biology of HIV InfectionsZIAAI001213 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MARTIN, MALCOLM · 2016 to 2025
$23.7MVirus TransmissionP50AI150464 · NIAID · UNIVERSITY OF UTAH · PI SUNDQUIST, WESLEY I. · 2019 to 2021
$14.9MRecombinant HIV-1 Env glycoprotein immunogens and antibodies production and structural characterizationP01AI138212 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MCGUIRE, ANDREW · 2019 to 2023
$9.2MGermline-targeting anti-idiotype antibodies as novel HIV-1 immunogensR21AI127249 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MCGUIRE, ANDREW · 2016 to 2017
$484kNIAID NIH HHS P01 AI100148NIAID NIH HHS P01 AI138212NIAID NIH HHS P50 AI150464NIAID NIH HHS R21 AI127249NIAID NIH HHS U54 AI170856NIAID NIH HHS UM1 AI144462
Abstract
Passive transfer of broadly neutralizing anti-HIV-1 antibodies (bNAbs) protects against infection, and therefore, eliciting bNAbs by vaccination is a major goal of HIV-1 vaccine efforts. bNAbs that target the CD4 binding site (CD4bs) on HIV-1 Env are among the most broadly active, but to date, responses elicited against this epitope in vaccinated animals have lacked potency and breadth. We hypothesized that CD4bs bNAbs resembling the antibody IOMA might be easier to elicit than other CD4bs antibodies that exhibit higher somatic mutation rates, a difficult-to-achieve mechanism to accommodate Env's N276
Indexed as
Animals, WildHIV-1AnimalsAnimals, Genetically ModifiedAntibodies, NeutralizingBinding SitesBroadly Neutralizing AntibodiesCD4 AntigensCell Adhesion MoleculesEpitopesHIV AntibodiesMacaca mulattaMicePolysaccharidesRabbitsAntibodies, NeutralizingBroadly Neutralizing AntibodiesCD4 AntigensCell Adhesion MoleculesEpitopesHIV AntibodiesPolysaccharides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.